Mikrobiyoloji Bulteni | VOL. 56
Read

Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens

Publication Date Apr 25, 2022

Abstract

It has been reported that many antibiotics used today, including the carbapenem group, fail to treat Klebsiella pneumoniae infections effectively. Despite many studies in recent years, the definitive treatment for carbapenem-resistant Klebsiella pneumoniae (CRKP) infections is still uncertain. In this study, it was aimed to investigate in vitro activities of colistin (COL) and meropenem (MEM), which are frequently used in the treatment of CRKP infections, and ceftazidime-avibactam (CZA), which is recently used in our country, alone or in combination against different CRKP isolates having different carbapenem resistance mechanisms andto analyze whether the presence of colistin resistance, which is an important problem in CRKP strains, influences the drug interaction results. This study was carried out in 42 K.pneumoniae isolates, which were isolated from various clinical samples as an infectious agent in Süleyman Demirel University Faculty of Medicine, Department of Medical Microbiology, Bacteriology Laboratory and whose carbapenem resistance was confirmed by carbapenemase inactivation test. The carbapenemase genes of the isolates were determined by the polymerase chain reaction (PCR) method. Antimicrobial susceptibilities of CRKP strains to CZA, MEM, and COL were determined by the broth microdilution method and in vitro synergy activities of dual combinations of these drugs were evaluated by checkerboard and time-kill methods. Statistical evaluation of categorical data was performed using Fisher's exact test, and p-value of ...

Concepts

Carbapenem-resistant Klebsiella Pneumoniae Carbapenem-resistant Klebsiella Pneumoniae Isolates Carbapenem-resistant Klebsiella Pneumoniae Strains Colistin Meropenem Ceftazidime-avibactam Carbapenem Resistance Positive Isolate Time-kill Test Time-kill Methods

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Coronavirus Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Introduction: Test solutions (Biotrue, renu Advanced [Bausch and Lomb], ACUVUE RevitaLens [Johnson and Johnson Vision], cleadew [Ophtecs corp.] or AOS...

Read More

Good health Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  2

Patient and public involvement in health care is considered indispensable in the way we conduct daily pediatric neurology practice, and in the develop...

Read More

Quality Of Education Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  5

Ingenta is not the publisher of the publication content on this website. The responsibility for the publication content rests with the publishers prov...

Read More

Gender Equality Research Articles published between Sep 26, 2022 to Oct 02, 2022

R DiscoveryOct 03, 2022
R DiscoveryArticles Included:  3

Introduction: As of early March 2022, the COVID-19 pandemic has killed more 5.9 million people worldwide, and infected more than 437 million.

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.